6
Oct 24 (Reuters) – Eli Lilly and Company: * LILLY PRESENTS FIRST CLINICAL DATA IN PLATINUM-SENSITIVE OVARIAN CANCER FOR ITS INVESTIGATIONAL, NEXT-GENERATION, FRΑ-TARGETING ADC AT ESMO 2026 * ELI LILLY
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
